



Neuroscience expert Dr David Cantor appointed to the board

Perth, Australia & Malta – 4 July 2018 – Neurotech International Limited (ASX: NTI) (**Neurotech or the Company**), developer of quality medical solutions improving the lives of children with autism, is pleased to announce the appointment of Dr David Cantor to the board as a Non-Executive Director.

A highly distinguished clinician, neuroscientist, program developer and a member of the Company's Scientific Advisory Board, Dr Cantor's career spans more than 40 years in the academic and clinical neuroscience sector. He is currently the CEO and Clinical Director of Mind and Motion Developmental Centers of Georgia, a multidisciplinary treatment facility providing a range of diagnostic and treatment services to children and adults seeking help with neurological disorders such as autism, ADHD, traumatic brain injury and sensory processing disorders. He is also the CEO and Managing Partner of BrainDx, an international software company that produces functional brain analytic software through computer assisted quantitative EEG (**QEEG**) reports and big database measures of brain development.

In addition to the above, Dr Cantor has held multiple board positions across various neuroscientific associations, including being a founding board member and current Chairman of the International Board of Quantitative Electrophysiology, established to maintain the highest quality of resources and examination procedures for clinicians and academicians with interests in quantitative electrophysiology. He is also Secretary of the International Society of Neurofeedback and Research and an advisory board member of the Innovative Health Foundation.

A prolific author of numerous journal articles and book contributions with regard to human development, developmental disorders, neurological disorders, and quantitative electrophysiology, he is highly sought after as a conference speaker for national and international organizations. Dr Cantor has been a reviewer for several professional and scientific journals. He is a Fellow of the National Academy of Neuropsychology and is also former President of the EEG and Clinical Neuroscience Society. He has also been a recipient of several grants in the field of brain research and accepted for special fellowships including Congressional Fellow of the American Psychological Association and the State of New York Intercampus Fellow in the area of brain research.

As a State of Connecticut Scholar, Dr Cantor received his Bachelors Degree with Distinction in Psychology from the University of Connecticut, his Masters and Doctorate in psychology from the State University of New York (Stony Brook), where his thesis was focused on QEEG characteristics of autism and which led to the first publication ever on quantitative EEG in autism. He has served as a faculty member for four Universities, and most recently added a Postdoctoral Masters of Science in Clinical Psychopharmacology from Farleigh Dickinson University. In 2017, he was the recipient of the ISNR Joel Lubar Award for outstanding contributions to the field of Neurofeedback therapy.

"We are very privileged to have someone of Dr Cantor's calibre join us on the board," said Neurotech's Chairman Peter O'Connor. "His life's work has been in the study and treatment of neurological disorders such as autism. Having served as a valued member of the Company's Scientific Advisory Board from January 2017, we are now pleased to formally welcome him as a member of the board and look forward to an exciting new chapter ahead."

-ends-

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device *Mente Autism* and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, *Mente Autism* helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and *Mente Autism* please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

For more information please contact:

Fleur Hudson

Company Secretary

fhudson@tribis.com.au

Tel: +61 (8) 9424 9360

Media enquiries:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420